SCHEMBL4832883

SCHEMBL4832883

COc1cc2c(cc1OC)C(CCN1CCC(O)(c3ccc(Cl)c(C(F)(F)F)c3)CC1)N(C(=O)C1CC1(Cl)Cl)CC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 14/20 0.48
OPRL1 P41146 6/20 0.48
OPRK1 P41145 9/20 0.46
HTR1A P08908 8/20 0.46
DRD2 P14416 8/20 0.46
DRD4 P21917 8/20 0.46
HTR2A P28223 8/20 0.46
HTR2C P28335 8/20 0.46
HTR7 P34969 8/20 0.46
OPRD1 P41143 7/20 0.46
HTR1D P28221 7/20 0.46
DRD3 P35462 7/20 0.46
HTR2B P41595 7/20 0.46
DRD1 P21728 6/20 0.46
DRD5 P21918 6/20 0.46
SLC6A2 P23975 6/20 0.46
SLC6A4 P31645 6/20 0.46
HTR6 P50406 6/20 0.46
SLC6A3 Q01959 6/20 0.46
HRH1 P35367 5/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4838194 0.89 MTNR1B (0.53) OPRM1OPRL1OPRK1HTR1ADRD2
SCHEMBL4839599 0.88 OPRM1 (0.48) OPRM1OPRL1OPRK1HTR1ADRD2
SCHEMBL6670152 0.77 OPRM1 (0.41) OPRM1OPRL1OPRK1HTR1ADRD2
SCHEMBL4833277 0.76 MTNR1B (0.61) OPRM1OPRL1OPRK1DRD2DRD1
SCHEMBL4710045 0.70 OPRM1 (0.72) OPRM1OPRL1OPRK1HTR1ADRD2
SCHEMBL11735355 0.70 OPRM1 (0.56) OPRM1OPRL1OPRK1HTR1ADRD2
SCHEMBL3858986 0.70 OPRM1 (0.65) OPRM1OPRL1OPRK1HTR1ADRD2
SCHEMBL3850816 0.69 OPRM1 (0.69) OPRM1OPRL1OPRK1HTR1ADRD2
SCHEMBL14282239 0.68 OPRM1 (0.76) OPRM1OPRL1OPRK1HTR1ADRD2
SCHEMBL4833288 0.68 NR1I2 (0.47) OPRM1OPRL1OPRK1DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 OPRM1 1618/4885OPRL1 480/4885OPRK1 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.